PL405977A1 - Therapeutic agent for internal application, accelerating anti-inflammatory and painkilling effects in the human and animal organisms - Google Patents
Therapeutic agent for internal application, accelerating anti-inflammatory and painkilling effects in the human and animal organismsInfo
- Publication number
- PL405977A1 PL405977A1 PL40597713A PL40597713A PL405977A1 PL 405977 A1 PL405977 A1 PL 405977A1 PL 40597713 A PL40597713 A PL 40597713A PL 40597713 A PL40597713 A PL 40597713A PL 405977 A1 PL405977 A1 PL 405977A1
- Authority
- PL
- Poland
- Prior art keywords
- inflammatory
- therapeutic agent
- human
- internal application
- animal organisms
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 4
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title abstract 2
- 230000003119 painkilling effect Effects 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 4
- 229940079593 drug Drugs 0.000 abstract 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 abstract 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 abstract 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 abstract 1
- 230000001760 anti-analgesic effect Effects 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 229960001680 ibuprofen Drugs 0.000 abstract 1
- 229960000905 indomethacin Drugs 0.000 abstract 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 abstract 1
- 229960000991 ketoprofen Drugs 0.000 abstract 1
- 229960002009 naproxen Drugs 0.000 abstract 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Środek leczniczy do stosowania wewnętrznego w postaci tabletek lub kapsułek zawiera trzy, cztery albo pięć substancji czynnych, wybranych ze ściśle określonych pięciu substancji czynnych wybranych ze ściśle określonych pięciu substancji czynnych o nazwach: diflofenak, naproksen, ibuprofen, ketoprofen, indometacyna. Na skutek efektu synergicznego powstały lek posiada znacznie zwiększone własności przeciwzapalne i przeciwbólowe w stosunku do własności leków opartych o jedną czynną substancję.The therapeutic agent for internal use in the form of tablets or capsules contains three, four or five active substances, selected from well-defined five active substances selected from the well-defined five active substances named: diflofenac, naproxen, ibuprofen, ketoprofen, indomethacin. Due to the synergistic effect, the resulting drug has significantly increased anti-inflammatory and analgesic properties compared to the properties of drugs based on one active substance.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL40597713A PL405977A1 (en) | 2013-11-08 | 2013-11-08 | Therapeutic agent for internal application, accelerating anti-inflammatory and painkilling effects in the human and animal organisms |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL40597713A PL405977A1 (en) | 2013-11-08 | 2013-11-08 | Therapeutic agent for internal application, accelerating anti-inflammatory and painkilling effects in the human and animal organisms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL405977A1 true PL405977A1 (en) | 2015-05-11 |
Family
ID=53040154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL40597713A PL405977A1 (en) | 2013-11-08 | 2013-11-08 | Therapeutic agent for internal application, accelerating anti-inflammatory and painkilling effects in the human and animal organisms |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL405977A1 (en) |
-
2013
- 2013-11-08 PL PL40597713A patent/PL405977A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201401028A1 (en) | PHARMACEUTICAL COMPOSITION, CONTAINING EMAGOGLIFLOZIN AND MEDICINES FOR OBESITY | |
| CL2019000431A1 (en) | Tetrahydro-pyrido [3,4-b] indoles estrogen receptor modulators and uses thereof. (divisional application 201700814) | |
| EP4512394A3 (en) | Dosage forms and use thereof | |
| BR112012017150A2 (en) | antibody formulation and therapeutic regimens. | |
| EA201690618A1 (en) | BLUTON TYROSINKINASE INHIBITORS | |
| MA38399A1 (en) | Formulation in tablet form, useful for treating acute heart failure and chronic heart failure | |
| IL232158A (en) | Piprazine-5,2-Deon derivatives, pharmaceutical preparations containing them and their use in the preparation of medicines | |
| GT201400059A (en) | DERIVATIVES OF ESTRA-1,3,5 (10), 16-TETRAEN-3-CARBOXAMIDE, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES | |
| BR112013010829B8 (en) | Intravenous pharmaceutical composition to provide relief from pain and/or inflammation | |
| EA201501164A1 (en) | SOLID PHARMACEUTICAL MEDICINE FORM | |
| EA201400737A1 (en) | DELIVERY SYSTEM ON THE BASIS OF A PELLET SET WITH IMMEDIATE release of an ACTIVE SUBSTANCE | |
| EA201590797A1 (en) | PREPARATIONS WITH THE MODIFIED PROBE RELEASE | |
| EP3784214C0 (en) | LIQUID ORAL PHARMACEUTICAL DOSAGE FORM | |
| MX389336B (en) | PHARMACEUTICAL FORMULATION. | |
| TR201821157T4 (en) | ORAL APPLICATION SOLID COMPOSITION CONTAINING IBANDRONIC ACID OR A PHARMACEUTICALLY ACCEPTABLE SALT AND VITAMIN D. | |
| MX2015009891A (en) | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE CRYSTAL PARTICLES OF SUITABLE MULTICOMPONENTS FOR USE IN INHALATION THERAPY. | |
| CL2012003119A1 (en) | Pharmaceutical composition for injection that compensates for an aqueous solution of ibuprofen and trometamol, in which the concentration of ibuprofen is between 2 and 6 mg / ml, the concentration of trometamol is between 1.8 and 5.8 mg / ml, and the pH is between 7.0 and 9.5; and its use for the treatment of pain, inflammation or fever. | |
| CL2016000182A1 (en) | Stable anti-tuberculosis pharmaceutical composition in a form of a coated tablet comprising isoniazid granules and rifapentin granules and their preparation process | |
| CL2016000183A1 (en) | Stable anti-tuberculosis pharmaceutical composition in a form of a redispersible tablet comprising isoniazid granules and rifapentin granules and their preparation process | |
| IL217519A (en) | Derivatives of tazarotene, pharmaceutical preparations containing them and their use in the preparation of medicines for the treatment of skin diseases | |
| EP2939663A4 (en) | FUSION-EXTRUDED PHARMACEUTICAL COMPOSITION FOR CONTROLLING RELEASE AND ORAL ADMINISTERED MEDICINE CONTAINING THE SAME | |
| MX387263B (en) | PROLONGED-RELEASE PHARMACEUTICAL COMPOSITION COMPRISING CYSTEAMINE OR SALT THEREOF. | |
| AR096223A1 (en) | NICOTINE PILL FOR ORAL ADMINISTRATION | |
| MX2017013633A (en) | Tamper-resistant fixed dose combination providing fast release of two drugs from particles. | |
| MX2017013634A (en) | FIXED DOSE COMBINATION RESISTANT TO HANDLING THAT PROVIDES A QUICK RELEASE OF TWO DRUGS FROM PARTICLES AND A POWDER. |